Overview
Safety information for IGF-1 LR3 depends on how extensively it has been studied in humans, how it is manufactured, and in what context it is used. Many catalog peptides have more preclinical than clinical safety data.
Common safety themes
For peptides in general, discussions of side effects often include:
- Local reactions at injection sites.
- Systemic symptoms such as headache, fatigue, or gastrointestinal upset.
- Uncertainties related to long-term exposure, interactions, and product quality.
Context and caveats
Absence of large, well-controlled human studies means that true risk profiles for many peptides remain incompletely defined. Regulatory status, manufacturing controls, and supervision by qualified clinicians are central to interpreting any safety conversation about IGF-1 LR3.
Sport & Anti-Doping Warning
IGF-1 LR3 is a long-acting insulin-like growth factor analogue noted by anti-doping experts as a potent, hard-to-detect performance enhancer; it is covered under the WADA category for peptide hormones and growth factors.
- >Overview of IGF-1 analogues and related substances under the WADA List
- >Educational article describing IGF-1 LR3 and its relevance to sport
Even without many public positive tests, laboratories treat IGF-1 LR3 as a high-priority target substance in the GH–IGF axis.